Griffith University Institute for Glycomics
The primary focus of the Institute for Glycomics, Griffith University is translating its drug, vaccine and diagnostic discoveries into social and economic benefit, locally and globally. 
Dr Chris Davis | General Manager
Institute for Glycomics
Griffith University | Gold Coast campus | QLD 4222 | Institute for Glycomics (G26) Room 4.24
T +617 555 27033| email
Dr Chris Davis obtained an honours degree and PhD in synthetic medicinal chemistry from Griffith University on the Gold Coast. For 2 years he worked in a biotechnology start-up company developing anti-bacterial drug candidates he co-invented during his PhD. Following the trade sale of that company he worked for commercialisation company, Uniquest Pty Ltd., in Brisbane seeking venture capital investment to enable the development of new drug and vaccine discoveries, together with licensing of drug and vaccine technologies to biotechnology and pharmaceutical companies.
In 2009 he returned to Griffith University as General Manager of the Institute for Glycomics where he leads a group of professionals dedicated to the strategic and operational development of the Institute, covering domestic and international business strategy, technology commercialisation, fund raising across the philanthropic, government, industry and private sectors, and general Institute operations.
Chris is also Chairman of Ausbiotech Ltd (Queensland Branch).
The primary focus of the Institute is translating its drug, vaccine and diagnostic discoveries into social and economic benefit, locally and globally.
The Institute specialises in research in the following areas:

Dr Danielle Stanisic
Associate Research Leader


Dr Stanisic has extensive expertise in parasitology, immunology, vaccinology and clinical trials with a major research focus on malaria vaccine development.

Danielle’s research has a translational focus and involves transitioning whole parasite vaccine candidates from pre-clinical animal studies into clinical development and their evaluation in clinical trials. She has established the experimental malaria challenge system at Griffith University for this purpose. She is also applying vaccine platforms developed within the Malaria Vaccine Program to other parasites of medical and veterinary importance e.g. Babesia.